Skip to content
approvedWeight Loss & Diabetes

Dulaglutide

Also known as: Trulicity, LY2189265

Dulaglutide is a long-acting GLP-1 receptor agonist consisting of a modified GLP-1 analog covalently linked to an engineered IgG4 Fc fragment, extending its half-life to approximately 5 days. FDA-approved in 2014 as Trulicity for type 2 diabetes, it is the most widely prescribed once-weekly GLP-1 RA globally. The REWIND trial demonstrated a 12% reduction in major adverse cardiovascular events, earning it an additional cardiovascular risk reduction indication.

4 cited references·5 researched benefits

Quick Answer

Dulaglutide (Trulicity) is a once-weekly injectable GLP-1 receptor agonist FDA-approved for type 2 diabetes. It consists of a GLP-1 analog fused to an IgG4 Fc fragment for extended half-life. Clinical trials show HbA1c reductions of 0.8–1.6% and weight loss of 2–5 kg. The landmark REWIND trial demonstrated 12% reduction in cardiovascular events, making it the first GLP-1 RA with proven CV benefit in a broad diabetic population.

Key Facts

Mechanism
Dulaglutide features two identical GLP-1 analog chains covalently linked to a modified human IgG4 Fc heavy chain via a small peptide linker. The GLP-1 analog portion contains amino acid substitutions (Gly8, Glu22, Gly36) that confer DPP-4 resistance and reduced immunogenicity, while the Fc fragment provides the extended half-life through FcRn-mediated recycling (similar to endogenous IgG). Upon binding the GLP-1 receptor, dulaglutide activates cAMP-dependent pathways in pancreatic beta cells, potentiating glucose-dependent insulin secretion and suppressing glucagon release. Central anorexigenic effects reduce appetite, while peripheral actions slow gastric emptying.
Research Status
approved
Half-Life
~5 days
Primary Use
Weight Loss & Diabetes
Table of Contents

Benefits

  • Glycemic control — reduces HbA1c by 0.8–1.6% across AWARD clinical trial program, with superior efficacy versus several comparatorsstrong
  • Cardiovascular risk reduction — REWIND trial showed 12% reduction in MACE (HR 0.88) in patients with and without established cardiovascular diseasestrong
  • Weight loss — modest 2–5 kg weight reduction; less weight loss than semaglutide but clinically meaningfulstrong
  • Renal protection — REWIND showed 15% reduction in new macroalbuminuria, suggesting kidney-protective effectsmoderate
  • Convenient once-weekly dosing — pre-filled single-use pen with hidden needle improves adherence versus daily injectionsstrong

Dosage Protocols

RouteDosage RangeFrequencyNotes
Subcutaneous injection0.75–4.5 mgOnce weeklyStart at 0.75 mg weekly for 4 weeks, escalate to 1.5 mg, then 3.0 mg and 4.5 mg as tolerated. Administer on the same day each week, any time of day. Pre-filled pen with hidden needle for ease of use.

Medical disclaimer

Dosage information is provided for educational reference only. Always follow your prescriber's instructions and consult a qualified healthcare provider before starting any peptide protocol.

Side Effects

  • Nausea — occurs in 12–21% of patients, typically mild and decreasing over time with dose titrationcommon
  • Diarrhea — reported in 8–13% of patients, usually transient during dose escalationcommon
  • Injection-site reactions — mild erythema or pruritus at injection site in ~2% of patientscommon
  • Pancreatitis — rare but serious; reported at rates of 0.1–0.3% in clinical trialsserious
  • Thyroid C-cell tumors — boxed warning based on rodent studies; clinical relevance in humans uncertainserious

Frequently Asked Questions

How does dulaglutide compare to semaglutide for weight loss?
Semaglutide produces significantly more weight loss than dulaglutide. In head-to-head trials, semaglutide 1 mg weekly showed ~5.8 kg loss versus ~3.0 kg for dulaglutide 1.5 mg weekly over 40 weeks. At higher doses approved for obesity (semaglutide 2.4 mg), weight loss reaches 15–17%. Dulaglutide is primarily positioned for glycemic control with cardiovascular benefits rather than weight management.
What was the REWIND trial and why was it important?
REWIND (Researching Cardiovascular Events with a Weekly Incretin in Diabetes) enrolled 9,901 patients with type 2 diabetes across 24 countries, with a median follow-up of 5.4 years — the longest of any GLP-1 RA cardiovascular outcomes trial. Unlike SUSTAIN-6 and LEADER, REWIND included patients with cardiovascular risk factors but without established disease (69% of enrollees). It showed a 12% reduction in MACE, demonstrating that dulaglutide provides primary prevention benefit, not just secondary prevention.
Is dulaglutide available as a generic or biosimilar?
As of early 2026, no biosimilar of dulaglutide has been approved in the US or EU. Eli Lilly holds patent protection through 2027–2029 depending on jurisdiction. Several biosimilar manufacturers have dulaglutide biosimilars in development. When available, biosimilars could reduce the cost significantly from the current ~$900/month US list price.
Can dulaglutide be used together with insulin?
Yes. Dulaglutide is FDA-approved for use in combination with basal insulin. The AWARD-9 trial demonstrated that adding dulaglutide 1.5 mg to insulin glargine reduced HbA1c by an additional 1.4% versus placebo, with 2 kg weight loss (versus 0.4 kg gain with placebo). However, it should not be combined with prandial insulin or other GLP-1 RAs.
How does the Trulicity pen work?
The Trulicity pen is a single-use, pre-filled auto-injector with a hidden needle — the patient never sees or handles the needle. After removing the cap and placing the pen flat against the skin (abdomen, thigh, or upper arm), pressing the green injection button automatically inserts the needle, delivers the dose, and retracts the needle. The injection takes about 5–10 seconds. The pen is disposed of after single use.

References

  1. 1
    Dulaglutide versus insulin glargine in patients with type 2 diabetes (AWARD-2)(2014)PubMed ↗
  2. 2
    Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND)(2019)PubMed ↗
  3. 3
    Efficacy and safety of dulaglutide 3.0 mg and 4.5 mg versus dulaglutide 1.5 mg in metformin-treated patients with type 2 diabetes (AWARD-11)(2021)PubMed ↗
  4. 4
    Comparative efficacy of once-weekly GLP-1 receptor agonists: a systematic review and network meta-analysis(2021)PubMed ↗

Latest Research

Last updated: 2026-02-19